Sean Bohen, Olema Oncology CEO

Af­ter re­fut­ing a sup­posed da­ta leak as 'fal­si­fied', Ole­ma re­veals first clin­i­cal da­ta for lead pro­gram — shares crash

Ole­ma On­col­o­gy had been prepar­ing to present the first clin­i­cal da­ta from its lead pro­gram at a con­fer­ence next week, but the biotech’s poster sup­pos­ed­ly leaked on­line Mon­day. In re­sponse, Ole­ma is­sued a state­ment say­ing the im­age was fal­si­fied, and pub­lished topline re­sults in a press re­lease Tues­day morn­ing.

The leaked poster os­ten­si­bly came from a pa­tient in the Phase I por­tion of the study, who post­ed on a dis­cus­sion fo­rum af­ter say­ing they com­plet­ed treat­ment and re­ceived a sum­ma­ry. Orig­i­nal­ly writ­ten on the ad­vo­ca­cy web­site In­, the fo­rum now leads to a 404 page, but some so­cial me­dia users man­aged to screen­shot the post.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.